Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 8/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19726325 | 0.90 | TLR4 (0.43) | TLR4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8746923 | 0.83 | TLR4 (0.47) | TLR4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL18059820 | 0.82 | TLR4 (0.46) | TLR4RAB9ANPC1MAPTTSHR | |
| SCHEMBL10229490 | 0.82 | TLR4 (0.44) | TLR4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23417814 | 0.81 | KCNH2 (0.41) | TLR4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10632667 | 0.81 | MAPT (0.44) | TLR4ALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL10178083 | 0.78 | TLR4 (0.55) | TLR4RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16491621 | 0.78 | TLR4 (0.57) | TLR4RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL8746914 | 0.78 | TLR4 (0.42) | TLR4RAB9ANPC1ALDH1A1KDM4E | |
| SCHEMBL18204522 | 0.77 | TLR4 (0.41) | TLR4RAB9ANPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957287-B2 | Methods and compositions to treat type-1 and type-2 diabetes | CORNELL UNIVERSITY (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170342097-A1 | METHODS AND COMPOSITIONS TO TREAT TYPE-1 AND TYPE-2 DIABETES | CORNELL UNIVERSITY | 2017-11-30 | — | — | US | disclosed |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342097-A1 | METHODS AND COMPOSITIONS TO TREAT TYPE-1 AND TYPE-2 DIABETES | IAPP, GPR119, IRS1 | TLR4 13/4885RAB9A 4224/4885NPC1 2023/4885 |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885RAB9A 1383/4885NPC1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.